Adaptimmune extends CFO Gavin Wood's departure to Sept 9, 2025; John Lunger exits Aug 31, 2025

Adaptimmune Therapeutics PLC

Gavin Wood's employment as CFO ends Sept 9, 2025 (extended from Aug 31) by redundancy; severance includes 12 months base salary, pro-rata bonus of £115,386, and 12 months healthcare.
John Lunger's employment as Chief Patient Supply Officer ends Aug 31, 2025 by redundancy; severance lump sum of $472,131 plus COBRA payment of $20,310.20.
Both officers' stock options continue vesting until their respective termination dates, with a 12-month post-termination exercise period for vested options.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.